Vancomycin intermediate-Resistant Staphylococcus aureus (VISA) Isolated from a patient who never received Vancomycin treatment

Zhu, Xuemei; Liu, Cailin; Gao, Sui; Lu, Yanfang; Chen, Zhongju; Sun, Ziyong

doi:10.1016/j.ijid.2014.12.038

Cited by 21 publications

(10 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For the penicillin binding protein encoded by the gene pbp2 , a SNP led to a significant amino acid substitution from the non-polar amino acid glycine to the basic amino acid arginine, which might have influenced the protein structure and thus its activity. Although, this specific mutation has not been previously described in the literature, the overexpression of pbp2 has been implicated in vancomycin-intermediate S. aureus (VISA) phenotype by several studies, demonstrating smaller colony size, lower growth rates, thicker cell walls, decreased lysostaphin susceptibility, and decreased beta-hemolysis 22 – 25 . Furthermore, the 534 bp deletion in the DHH domain of the GGDEF domain protein containing phosphodiesterase (GdpP) may contribute to the observed phenotypic alterations by impairment of enzyme activity.…”

Section: Discussionmentioning

confidence: 99%

Emergence of a dalbavancin induced glycopeptide/lipoglycopeptide non-susceptible Staphylococcus aureus during treatment of a cardiac device-related endocarditis

Kussmann

Karer

Obermueller

et al. 2018

Emerging Microbes & Infections

View full text Add to dashboard Cite

In the present study, we demonstrated the emergence of dalbavancin non-susceptible and teicoplanin-resistant Staphylococcus aureus small colony variants which were selected in vivo through long-term treatment with dalbavancin. A 36-year-old man presented with a cardiac device-related S. aureus endocarditis and received long-term therapy with dalbavancin. Consecutively, two glycopeptide/lipoglycopeptide susceptible and two non-susceptible S. aureus isolates were obtained from blood cultures and the explanted pacemaker wire. The isolates were characterized by: standard typing methods, antimicrobial susceptibility testing, auxotrophic profiling, proliferation assays, scanning and transmission electron microscopy, as well as whole genome sequencing. The isolated SCVs demonstrated a vancomycin-susceptible but dalbavancin non-susceptible and teicoplanin-resistant phenotype whereof the respective MICs of the last isolate were 16- and 84-fold higher than the susceptible strains. All four strains were indistinguishable or at least closely related by standard typing methods (spa, MLST, and PFGE), and whole genome sequencing revealed only eight sequence variants. A consecutive increase in cell wall thickness (up to 2.1-fold), an impaired cell separation with incomplete or multiple cross walls and significantly reduced growth rates were observed in the present study. Therefore, the mutations in pbp2 and the DHH domain of GdpP were identified as the most probable candidates due to their implication in the biosynthesis and metabolism of the staphylococcal cell wall. For the first time, we demonstrated in vivo induced dalbavancin non-susceptible/teicoplanin resistant, but vancomycin and daptomycin susceptible S. aureus SCVs without lipopeptide or glycopeptide pretreatment, thus, indicating the emergence of a novel lipoglycopeptide resistance mechanism.

show abstract

Section: Discussionmentioning

confidence: 99%

Emergence of a dalbavancin induced glycopeptide/lipoglycopeptide non-susceptible Staphylococcus aureus during treatment of a cardiac device-related endocarditis

Kussmann

Karer

Obermueller

et al. 2018

Emerging Microbes & Infections

View full text Add to dashboard Cite

show abstract

“…VISA strains with a heterogeneous genetic background were reported in several studies from Iran [ 1 ], India [ 40 ], US [ 38 ], Bangladesh [ 42 ], New Zealand [ 39 ] and China [ 43 ]. There is not enough information about the prevalence rate of VISA strains in Iran; however, in 2005, Saderi et al reported the prevalence rate of 1.8% for VISA isolated from clinical samples based on the evaluation of four teaching hospitals in Tehran [ 44 ].…”

Section: Discussionmentioning

confidence: 99%

Molecular characterization of vancomycin-resistant Staphylococcus aureus strains isolated from clinical samples: A three year study in Tehran, Iran

et al. 2017

View full text Add to dashboard Cite

“…Because the high failure rate of vancomycin treatment for MRSA infections is associated with higher vancomycin MICs, the CLSI reduced the vancomycin susceptibility breakpoint for S. aureus from MIC value of 4–2 mg/L to improve the predictive susceptibility result (CLSI, 2016). In China, although VRSA is not by far found, the prevalence of hVRSA was more than 10% (Sun et al, 2009) and VISA has been reported (Zhang et al, 2013; Zhu et al, 2015). The elevated vancomycin MICs among MRSA clinical isolates in China should be of concern.…”

Section: Introductionmentioning

confidence: 99%

Decreased Vancomycin MICs among Methicillin-Resistant Staphylococcus aureus Clinical Isolates at a Chinese Tertiary Hospital over a 12-year Period

Guo

Wang

et al. 2016

Front. Microbiol.

View full text Add to dashboard Cite

The increased vancomycin minimum inhibitory concentration values (MICs) for methicillin-resistant Staphylococcus aureus (MRSA) isolates are associated with treatment failure and mortality of MRSA infections. In the present study, 553 non-duplicate MRSA isolates from various specimens of patients with infections at a Chinese tertiary hospital from January 2003 to December 2014, were selected randomly for investigating the shift of vancomycin MICs determined by E-test method. The percentages of the MRSA isolates with vancomycin MICs of ≥2.0, 1.5, 1.0, and ≤0.75 mg/L were 16.3% (90/553), 38.5% (213/553), 35.6% (197/553), and 9.9% (55/553), respectively. The highest geometric mean MIC (GM MIC) value (1.648 mg/L) and the lowest GM MIC (0.960 mg/L) were found in the first year (2003) and the last year (2014) over the study period, with significant difference (p < 0.05). The GM MICs over the study period fluctuated by year, with the elevated values in 2005, 2011, and 2013 and the decreased values in other years relative to the respective former year. The vancomycin GM MIC (1.307 mg/L) for MRSA isolates from sputum was the highest relative to that for the MRSA isolates from other specimens. By contrast, the vancomycin GM MIC value (1.156 mg/L) for MRSA isolates from pus was the lowest, with similar value to that for the isolates from blood. The vancomycin GM MICs in period I (2003–2005), period II (2006–2008), period III (2009–2011), and period IV (2012–2014) were 1.501, 1.345, 1.177, and 1.139 mg/L, respectively, with the continuous decreased trend. Compared with period I, the vancomycin GM MIC for MRSA isolates in period IV was significantly lower (p < 0.01), with a 1.318- fold decrease. The percentages of the isolates with vancomycin MIC ≥2 mg/L in four periods were 25, 15.6, 15.2, and 12%, respectively, with a continuous decrease. While the percentages of the isolates with vancomycin MIC ≤0.75 mg/L in four periods increased from 1.7% in period I to 19.3% in period IV. Taken together, a decreased trend in vancomycin MICs for MRSA isolates from a Chinese tertiary teaching hospital has been found. This pnenomenon was mainly associated with a decrease in the proportion of the MRSA isolates with vancomycin MIC ≥2 mg/L and an increase in the proportion of the MRSA isolates with vancomycin MIC ≤0.75 mg/L.

show abstract

Vancomycin intermediate-Resistant Staphylococcus aureus (VISA) Isolated from a patient who never received Vancomycin treatment

Abstract: This is the first report of VISA found in central China from a patient who had never received vancomycin treatment.

Cited by 21 publications

References 36 publications

Emergence of a dalbavancin induced glycopeptide/lipoglycopeptide non-susceptible Staphylococcus aureus during treatment of a cardiac device-related endocarditis

Emergence of a dalbavancin induced glycopeptide/lipoglycopeptide non-susceptible Staphylococcus aureus during treatment of a cardiac device-related endocarditis

Molecular characterization of vancomycin-resistant Staphylococcus aureus strains isolated from clinical samples: A three year study in Tehran, Iran

Decreased Vancomycin MICs among Methicillin-Resistant Staphylococcus aureus Clinical Isolates at a Chinese Tertiary Hospital over a 12-year Period

Contact Info

Product

Resources

About